PSIL

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-295.1K ExitQ4 2024 $295k -- $21.46

News

newsfilecorp.comPacifica Silver Reports Strong Gold-Silver Intercepts at Claudia Project and Extends Justina Vein to 600 Metres in Strike Lengthnewsfilecorp.comJun 11

prnewswire.comAdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapiesprnewswire.comApr 20

newsfilecorp.comPacifica Silver Reports Initial Phase II Drill Results at Claudia with Multiple High-Grade Intercepts at the Aguilareña Areanewsfilecorp.comApr 14

newsfilecorp.comPacifica Silver Announces Adoption of Semi-Annual Reportingnewsfilecorp.comApr 9

newsfilecorp.comPacifica Silver Provides Exploration Update at Claudia Silver-Gold Project; Grants Incentive Stock Optionsnewsfilecorp.comApr 2

Trade PSIL

About AdvisorShares Psychedelics ETF

This actively managed Exchange Traded Fund (ETF) endeavors to meet its investment goals by typically allocating a minimum of 80% of its total net assets (including any capital secured through borrowing for investment purposes) into the securities of specific companies. To be eligible for inclusion, these companies must either derive at least half of their net revenue from, or commit 50% or more of their assets to, psychedelic compounds, their derivatives, or other financial instruments exhibiting similar economic characteristics. The fund's primary holdings consist of publicly traded life sciences firms focused on psychedelic medical treatments, in addition to other businesses involved in the broader psychedelics sector. It is important to note that this fund maintains a concentrated, non-diversified portfolio.

IPO Date: Sep 16, 2021

Market Data

Open: $20.15
High: $20.15
Low: $19.43
Volume: 15.6K
Avg Volume: 37.9K
52W High: $22.49
52W Low: $13.40

Valuation

Market Cap: $20M
Dividend Yield: 1.72%

Financials

Financial statement snapshot is not available yet.

Events

DividendDec 22

$1.68387